Table 3.
Characteristics of the Study Participants With and Without High-Grade Squamous Intraepithelial Lesions at Baseline or During Follow-Up
| HSIL, n = 81 (16.4%) | No HSIL, n = 412 (83.6%) | Total, n = 493 (100%) | p | |
|---|---|---|---|---|
| Age, in years | 38 (14) | 38 (17) | 38 (16.8) | 0.807 |
| Active smoker | 37 (46.7%) | 181 (44.6%) | 218 (44.9%) | 0.784 |
| Time since HIV diagnosis, in years | 11 (7.5) | 9 (9) | 9 (9) | 0.065 |
| Any history of AIDS-defining illness | 14 (17.3%) | 60 (14.6%) | 74 (15.0%) | 0.501 |
| Baseline CD4+ lymphocyte count, cells/μL | 445 (427) | 429 (402) | 438 (408) | 0.761 |
| Nadir CD4+ lymphocyte count, cells/μL | 340 (337) | 363 (276) | 354 (281) | 0.138 |
| Nadir CD4+ lymphocyte count <200 cells/μL | 24 (30.0%) | 93 (23.1%) | 117 (24.3%) | 0.200 |
| HCV positive antibodies | 5 (6.2%) | 13 (3.2%) | 18 (3.7%) | 0.194 |
| Previous diagnosis of any STI | 61 (75.3%) | 286 (69.4%) | 347 (70.4%) | 0.351 |
| Syphilis | 40 (49.4%) | 190 (46.1%) | 230 (46.7%) | 0.590 |
| Gonorrhea | 16 (19.8%) | 63 (15.3%) | 79 (16.0%) | 0.322 |
| Chlamydia trachomatis infection | 6 (7.4%) | 30 (7.3%) | 36 (7.3%) | 1.000 |
| Anogenital condyloma acuminata | 34 (42.0%) | 117 (28.4%) | 151 (30.6%) | 0.015 |
| Baseline HR-HPV | 78 (96.3%) | 316 (76.7%) | 394 (79.9%) | <0.001 |
| Baseline HPV-16 | 48 (59.3%) | 122 (29.6%) | 170 (34.5%) | <0.001 |
| Baseline HPV-18 | 22 (27.2%) | 50 (12.1%) | 72 (14.6%) | 0.001 |
| Baseline pHR-HPV | 73 (90.1%) | 290 (70.4%) | 363 (73.6%) | <0.001 |
Qualitative variables are expressed as total numbers and percentages; quantitative variables are expressed as medians and interquartile ranges.
HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR-HPV, high-risk HPV; HSIL, high-grade squamous-intraepithelial lesion; pHR-HPV, pooled high-oncogenic risk human papillomavirus; STI, sexually transmitted infection.